Ticker	Market Cap	P/E Ratio	Revenue Growth	Net Margin	EPS	ROE	Debt/Equity	Dividend Yield	52W High	52W Low
MAZE	1.72 B	-	-	0.00%	-$2.48	-37.35%	0.13x	0.00%	$53.65	$21.95
SEPN	1.89 B	-	22375.60%	-24.51%	-$0.54	-6.34%	0.06x	0.00%	$51.10	$17.55
XERS	1.86 B	-	28.70%	-5.12%	-$0.10	-	-	0.00%	$11.42	$5.25
TRVI	1.80 B	-	-	0.00%	-$0.35	-19.66%	0.00x	0.00%	$20.22	$9.82
TRLV	1.77 B	-	-10.30%	-41.55%	-$2.43	-47.65%	0.75x	0.00%	$13.28	$4.62

Peer Valuation & Performance Analysis

Peer group analysis for Maze Therapeutics, Inc. (MAZE) compared to its primary competitors (including SEPN, XERS, TRVI) reveals distinct metrics. MAZE trades at a valuation premium compared to its competitors, with a P/E ratio of -12.5x versus the peer average of -54.3x (representing a -77% premium). This indicates that the market expects superior growth or commands a quality premium for MAZE. Additionally, it boasts superior profitability with a net margin of 0.0% compared to the peer average of -17.8%, demonstrating strong cost controls and pricing power.

Peer Performance Rankings

Ranking comparison across key performance metrics

P/E Ratio (Lower is Better)

Revenue Growth

🥇SEPN↑

+22375.6%

🥈XERS↑

+28.7%

🥉TRLV↓

-10.3%

Net Profit Margin

🥇MAZE↓

0.0%

🥈TRVI↓

0.0%

🥉XERS↓

-5.1%

4thSEPN↓

-24.5%

5thTRLV↓

-41.5%

Financial Rankings Summary

• MAZE ranks #0 in P/E ratio, #0 in revenue growth, and #1 in profit margins

• Average ranking: #0 - 🎯 Top-tier fundamentals relative to peer group

• Rankings based on actual financial data from company reports

Historical Trading Data

Price and volume data with customizable timeframes

Timeframe:

Showing 15 of 15 trading sessions from the last 15 days

Date	Open	High	Low	Close	Volume	Daily Change
2026-10-23	$31.86	$31.86	$30.54	$31.01	512,935	-2.94%
2026-10-22	$32.45	$32.95	$31.71	$31.95	891,100	-1.93%
2026-10-21	$32.52	$33.19	$31.55	$32.58	1,068,300	+0.40%
2026-10-20	$29.82	$32.61	$29.58	$32.45	1,569,200	+9.26%
2026-10-19	$28.01	$30.57	$27.83	$29.70	1,296,000	+7.88%
2026-10-16	$27.50	$27.89	$26.72	$27.53	1,018,500	+0.18%
2026-10-15	$26.59	$28.11	$26.46	$27.48	540,000	+4.77%
2026-10-14	$26.51	$27.09	$25.96	$26.23	835,700	-1.61%
2026-10-13	$27.54	$28.24	$26.57	$26.66	615,100	-3.75%
2026-10-12	$27.11	$29.32	$26.66	$27.70	1,437,900	+2.18%
2026-10-09	$25.88	$27.19	$25.88	$27.11	670,900	+4.75%
2026-10-08	$25.97	$26.44	$25.05	$25.88	903,000	-1.41%
2026-10-07	$26.30	$26.89	$25.87	$26.25	823,900	-0.68%
2026-10-06	$26.74	$26.91	$25.79	$26.43	682,800	+0.00%
2026-10-05	$26.67	$27.03	$25.78	$26.43	588,000	+0.00%

Explore More Analysis for MAZE

Additional research, tools, and technical breakdowns

Stock Analyzer Report

Deep-dive automated research and stock rating report.

DCF Fair Value Calculator

Discounted cash flow model and intrinsic value projection.

AI Price Predictions

Multi-scenario price predictions and consensus targets.

Insider Activity Tracker

Track buying/selling behavior of corporate insiders.

Earnings Calendar

Track upcoming and historical corporate earnings reports.

Market Insights & Research

Read the latest analysis articles and expert research.

Maze Therapeutics, Inc.(MAZE)Stock Performance & ReturnsNASDAQ

Returns, drawdowns and benchmark comparison

Peer Comparison